Insider Buying: Zenas BioPharma (NASDAQ:ZBIO) Director Purchases $3,000,000.00 in Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO) Director Fairmount Funds Management Llc purchased 150,000 shares of Zenas BioPharma stock in a transaction that occurred on Tuesday, March 31st. The shares were bought at an average cost of $20.00 per share, for a total transaction of $3,000,000.00. Following the completion of the transaction, the director directly owned 2,359,025 shares in the company, valued at $47,180,500. This represents a 6.79% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this link.

Zenas BioPharma Price Performance

NASDAQ ZBIO opened at $21.46 on Friday. The company has a quick ratio of 5.61, a current ratio of 5.61 and a debt-to-equity ratio of 0.32. Zenas BioPharma, Inc. has a fifty-two week low of $6.11 and a fifty-two week high of $44.60. The business has a 50 day moving average price of $23.17 and a two-hundred day moving average price of $27.28. The stock has a market cap of $1.23 billion, a PE ratio of -2.75 and a beta of -0.54.

Zenas BioPharma (NASDAQ:ZBIO) last posted its quarterly earnings data on Monday, March 16th. The company reported ($4.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by ($3.32).

Institutional Investors Weigh In On Zenas BioPharma

Institutional investors and hedge funds have recently made changes to their positions in the company. SR One Capital Management LP lifted its stake in Zenas BioPharma by 2.6% during the fourth quarter. SR One Capital Management LP now owns 5,037,854 shares of the company’s stock worth $182,924,000 after purchasing an additional 126,315 shares during the last quarter. NEA Management Company LLC raised its holdings in shares of Zenas BioPharma by 28.9% during the fourth quarter. NEA Management Company LLC now owns 3,523,219 shares of the company’s stock worth $127,928,000 after purchasing an additional 789,500 shares during the period. Federated Hermes Inc. raised its holdings in shares of Zenas BioPharma by 45.9% during the fourth quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock worth $98,603,000 after purchasing an additional 853,740 shares during the period. Vanguard Group Inc. lifted its position in shares of Zenas BioPharma by 25.0% in the 4th quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock worth $52,761,000 after buying an additional 290,307 shares during the last quarter. Finally, Polar Capital Holdings Plc bought a new position in shares of Zenas BioPharma in the 4th quarter worth about $38,402,000.

Analyst Ratings Changes

A number of analysts have recently issued reports on ZBIO shares. Guggenheim lifted their target price on Zenas BioPharma from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Monday, March 16th. Morgan Stanley increased their price target on Zenas BioPharma from $19.00 to $21.00 and gave the company an “equal weight” rating in a report on Tuesday, March 17th. HC Wainwright restated a “buy” rating and set a $44.00 price objective on shares of Zenas BioPharma in a research note on Tuesday, March 17th. Wall Street Zen downgraded Zenas BioPharma from a “hold” rating to a “strong sell” rating in a report on Saturday, March 21st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zenas BioPharma in a research report on Friday, March 27th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $44.14.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.